The Effect of Nano-Albumin Paclitaxel on the Early Postoperative Recurrence of Primary Liver Cancer

• DOI: 10.1166/jnn.2020.18710
• Publication Date: 2020-07-26T04:35:53Z
• Authors: Xinhong Wang; Min Li; Jing Wang; Yihong Cao
• Keywords: Liver function

This study aimed at investigating the clinical effect and safety of albumin binding paclitaxel (Nab-P) for first-line treatment advanced primary liver cancer. Clinical data 23 patients with cancer, who were treated in tumor Department PLA General Hospital from May 2014 to December 2015, analyzed retrospectively. The divided into an observation group a control group, according their plan. (12) received Nab-P (5 cases combined tegeor, 5 capecitabine, 2 single drug), (11) gemcitabine oxaliplatin. Each cycle lasted 21 days, was evaluated once every two cycles, while adverse reactions assessed after cycle. survival rates different groups compared using chi-square test or Fisher's exact test, Kaplan Meier curve, log rank test. Results all used evaluate efficacy reactions. In there partial remission, 7 disease stability, 3 progress; 4 progress. There no significant difference rate between (75% vs. 64%, χ² = 0.350, P > 0.05). median progression free time (5.1 (2.7-6.7) months versus 4.3 (2.5-54) months, =0.647, No serious side effects observed any groups. Among some PLT toxicity increased AST (Aspartate transaminase) incidence, which showed statistically (χ² 5.490, 0.036 PLT; 6.135, 0.027 AST). new Nab-P-based drug regimen has good against are tolerable. However, sample size this small further studies larger samples required verify results.